Dmitry Balyasny’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

Dmitry Balyasny’s Portfolio LHDX Stock Details LHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-271,030	Closed	-$30.1K	–	3380
2022 Q4	$30.1K	Sell	271,030 -55,168	-17%	-$35.2K	﹤0.01%	2422
2022 Q3	$346K	Hold	326,198	–	–	﹤0.01%	2150
2022 Q2	$607K	Buy	+326,198	New	+$793K	﹤0.01%	1919
2021 Q4	–	Sell	-93,439	Closed	-$710K	–	2709
2021 Q3	$710K	Buy	93,439 +57,224	+158%	+$483K	﹤0.01%	1410
2021 Q2	$240K	Sell	36,215 -64,393	-64%	-$406K	﹤0.01%	1694
2021 Q1	$1.22M	Buy	+100,608	New	+$2M	0.01%	1183

Other funds holding LHDX

Eclipse Ventures Palo Alto, California $2.57B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Resolute Advisors San Francisco, California $417M AUM 60.99% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Dmitry Balyasny's LHDX Position: Q1 2023 in Review

Dmitry Balyasny sold out of Lucira Health, Inc. Common Stock (LHDX) in Q1 2023, closing a stake of 271,030 shares — an estimated $30.1K sold.

Dmitry Balyasny first reported a position in LHDX in Q1 2021 and held it in 6 quarters. The position peaked at $1.22M in Q1 2021. 6 funds tracked by Wall St. Rank hold LHDX as of Q1 2023.

Dmitry Balyasny reported no remaining Lucira Health, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Dmitry Balyasny sold 271,030 Lucira Health, Inc. Common Stock shares in Q1 2023, an estimated $30.1K.
Dmitry Balyasny first reported a position in Lucira Health, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Dmitry Balyasny's Lucira Health, Inc. Common Stock position peaked at $1.22M in Q1 2021.
6 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.